15 min listen
TRIM63 as a biomarker for MiT family RCC
FromModPath Chat
ratings:
Length:
21 minutes
Released:
Aug 3, 2021
Format:
Podcast episode
Description
In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.Study by Mehra et al, TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 34, 1596-1607, 2021. https://www.nature.com/articles/s41379-021-00803-z. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Released:
Aug 3, 2021
Format:
Podcast episode
Titles in the series (58)
ALK rearranged renal cell carcinoma (ALK-RCC): The host discusses with Professor Ondrej Hes, from the Charles University in the Czech Republic, his recent multi-institutional study that further defines ALK-RCC as a genetically distinct renal cancer type showing a heterogeneous histomorphology. by ModPath Chat